News

Vemurafenib looks promising for several nonmelanoma malignancies


 

FROM THE NEW ENGLAND JOURNAL OF MEDICINE

References

Vemurafenib showed promising activity against several nonmelanoma cancers carrying BRAF V600 mutations in a preliminary phase II study reported online Aug. 20 in the New England Journal of Medicine.

Vemurafenib, a selective oral inhibitor of the BRAF V600 kinase, has produced a 50% response rate and improved survival in patients with metastatic melanoma expressing BRAF V600 mutations. Researchers subsequently identified the same mutations in numerous other tumor types, many of which are aggressive and some of which have no effective treatment. But the drug’s efficacy against these malignancies has not been examined systematically until now, because of “the large number of tumor types involved, the low frequency of BRAF V600 mutations, and the rarity of some of the cancers,” said Dr. David M. Hyman of Memorial Sloan Kettering Cancer Center, New York, and his associates.

vitanovski/ThinkStock

To perform such an exploratory investigation, Dr. Hyman and his colleagues used a “basket” study design allowing enrollment of 122 patients from 23 medical centers worldwide who had advanced BRAF-V600–positive non–small cell lung cancer, ovarian cancer, colorectal cancer, cholangiocarcinoma, breast cancer, multiple myeloma, Erdheim-Chester disease, Langerhans-cell histiocytosis, anaplastic thyroid cancer, or “other” malignancies. A total of 95 of these participants received vemurafenib monotherapy, and 27 who had colorectal cancer received vemurafenib plus cetuximab combination therapy.

After 8 weeks of treatment, many patients showed partial or complete responses. Continued treatment often yielded tumor regression and prolonged stabilization of disease. The agent was particularly effective against non–small cell lung cancer, with an objective response rate of 42% among 19 evaluable patients, and against Erdheim-Chester disease and Langerhans-cell histiocytosis, with an objective response rate of 43% among 14 evaluable patients. The latter two malignancies are closely related orphan diseases with no approved therapies; none of these patients showed disease progression while taking vemurafenib, Dr. Hyman and his associates said (New Engl. J. Med. 2015 Aug 20 [doi:10.1056/NEJMoa1502309]).

Vemurafenib also showed modest but promising activity against anaplastic thyroid cancer, cholangiocarcinoma, anaplastic pleomorphic xanthoastrocytoma, salivary-duct cancer, clear-cell sarcoma, low-grade serous ovarian cancer, high-grade glioblastoma, anaplastic ependymoma, pancreatic cancer, and carcinoma of unknown primary type. Most of these cancers have limited therapeutic options. However, these results must be interpreted with caution because the largest of these subgroups of patients only comprised 8 patients.

Recommended Reading

Consolidation chemotherapy after concurrent chemoradiation failed to improve outcomes in NSCLC
MDedge Hematology and Oncology
FDA panel says benefits of necitumumab for squamous NSCLC outweigh risks
MDedge Hematology and Oncology
Gefitinib approved for first-line EGFR-positive metastatic NSCLC
MDedge Hematology and Oncology
ASCO 2015: from data and learning, to daily practice
MDedge Hematology and Oncology
Oncogenic drivers and immunotherapy: staying one step ahead of lung cancer
MDedge Hematology and Oncology
Harnessing new data on immunotherapies
MDedge Hematology and Oncology
Lung cancer biomarker moves into the clinic
MDedge Hematology and Oncology
Limited resection inferior for elderly with early NSCLC
MDedge Hematology and Oncology
Solid histology predicts poor survival in resected lung adenocarcinoma
MDedge Hematology and Oncology
Immune-related patterns of response present challenges
MDedge Hematology and Oncology